InMed Pharmaceuticals M&A Deal with Mentari Therapeutics, Inc.
InMed Pharmaceuticals Inc. (now renamed Mentari Therapeutics, Inc.) completed its previously announced business combination with private Delaware corporation Mentari Therapeutics on November 6, 2026. This filing provides the required historical financial statements and management's discussion for the acquired Mentari entity for the period ended September 30, 2026. The combined company now trades on Nasdaq under the ticker 'MTRI'.
InMed Pharmaceuticals Signs $490M M&A Deal with Mentari Therapeutics, Inc.
InMed Pharmaceuticals Inc. (renamed Mentari Therapeutics, Inc.) completed its business combination with private Delaware corporation Mentari Therapeutics, Inc. on November 6, 2026. The transaction included a pre-closing financing that raised $490 million in aggregate gross proceeds. The combined company will focus on developing therapies for migraine prevention and is led by the Mentari management team.
InMed Pharmaceuticals Signs $490M M&A Deal with InMed Pharmaceuticals Inc.
Mentari Therapeutics completed its merger with InMed Pharmaceuticals Inc. and began trading on Nasdaq under the ticker 'MTRI'. In connection with the closing, the company completed $490 million in private placement financings to fund its pipeline of migraine prevention biologics, including MT-001 and MT-002.
InMed Pharmaceuticals M&A Deal with Mentari Therapeutics, Inc.
InMed Pharmaceuticals provided a status update on its pending merger with Mentari Therapeutics, which is expected to close in Q4 2026. Mentari has announced private placements totaling $490 million to support operations through 2029, and InMed shareholders will vote on the transaction at a meeting on November 4, 2026.
Counterparty
Mentari Therapeutics, Inc.
“We are approaching an important milestone in our proposed merger with Mentari Therapeutics, with our annual general and special meeting scheduled for November 4, 2026. Our focus remains on completing the transaction, which we believe provides shareholders with an opportunity to participate in the development of Mentari's migraine prevention pipeline.”
InMed Pharmaceuticals received a deficiency notice from Nasdaq for failing to maintain the minimum $2.5 million shareholders' equity requirement for continued listing. The company reported shareholders' equity of $1,075,007, largely due to expenses related to its pending merger with Mentari Therapeutics. InMed expects to regain compliance upon the closing of the merger, which is anticipated to bring approximately $490 million in gross proceeds to the combined company.